Abciximab as a bridging strategy to overcome morphine–prasugrel interaction in STEMI patients
| العنوان: | Abciximab as a bridging strategy to overcome morphine–prasugrel interaction in STEMI patients |
|---|---|
| المؤلفون: | Siller‐Matula, Jolanta M., Specht, Simon, Kubica, Jacek, Alexopoulos, Dimitrios, De Caterina, Raffaele, Hobl, Eva‐Luise, Jilma, Bernd, Christ, Günter, Lang, Irene M. |
| بيانات النشر: | John Wiley and Sons Inc., 2016. |
| سنة النشر: | 2016 |
| مصطلحات موضوعية: | Male, Morphine, Platelet Aggregation, Platelet Function Tests, Abciximab, Antibodies, Monoclonal, Middle Aged, Immunoglobulin Fab Fragments, Humans, ST Elevation Myocardial Infarction, Drug Interactions, Female, Prospective Studies, Prasugrel Hydrochloride |
| الوصف: | The present study investigated whether the glycoprotein (GP)IIb/IIIa receptor blocker abciximab might be a successful bridging strategy to achieve adequate levels of platelet inhibition rapidly in cases where prasugrel is used in morphine-pretreated ST-elevation myocardial infarction (STEMI) patients.In a prospective observational cohort study, 32 patients presenting with STEMI were given prasugrel at a loading dose of 60 mg. Patients were stratified into four groups, according to morphine and/or abciximab use. Adenosine diphosphate (ADP)-induced platelet aggregation was measured at four time points: at baseline, and at 2 h, 1 day and 2 days after prasugrel loading.Morphine use was associated with a three-fold higher level of ADP-induced platelet aggregation 2 h after prasugrel loading compared with no morphine/no abciximab (P = 0.019). However, when abciximab was infused in the catheterization laboratory, the effect of morphine on ADP-induced platelet aggregation disappeared (P = 0.884). This interaction was also seen in the presence of high on-treatment platelet reactivity (HTPR) at 2 h; while HTPR was seen in 88% of morphine users/no abciximab users, it was found in only 17-20% in the three other groups (P = 0.003). The effect of morphine disappeared by day 1 - 2.The infusion of the GPIIb/IIIa receptor blocker abciximab allows immediate and efficient platelet inhibition in STEMI patients concomitantly receiving the oral ADP receptor blocker prasugrel and morphine. |
| اللغة: | English |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=pmid________::0a892e0d75cf4b278917e29b9d016eb1Test https://europepmc.org/articles/PMC5061801Test/ |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.pmid..........0a892e0d75cf4b278917e29b9d016eb1 |
| قاعدة البيانات: | OpenAIRE |
| ResultId |
1 |
|---|---|
| Header |
edsair OpenAIRE edsair.pmid..........0a892e0d75cf4b278917e29b9d016eb1 797 3 unknown 796.859497070313 |
| PLink |
https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.pmid..........0a892e0d75cf4b278917e29b9d016eb1&custid=s6537998&authtype=sso |
| FullText |
Array
(
[Availability] => 0
)
|
| Items |
Array
(
[Name] => Title
[Label] => Title
[Group] => Ti
[Data] => Abciximab as a bridging strategy to overcome morphine–prasugrel interaction in STEMI patients
)
Array ( [Name] => Author [Label] => Authors [Group] => Au [Data] => <searchLink fieldCode="AR" term="%22Siller‐Matula%2C+Jolanta+M%2E%22">Siller‐Matula, Jolanta M.</searchLink><br /><searchLink fieldCode="AR" term="%22Specht%2C+Simon%22">Specht, Simon</searchLink><br /><searchLink fieldCode="AR" term="%22Kubica%2C+Jacek%22">Kubica, Jacek</searchLink><br /><searchLink fieldCode="AR" term="%22Alexopoulos%2C+Dimitrios%22">Alexopoulos, Dimitrios</searchLink><br /><searchLink fieldCode="AR" term="%22De+Caterina%2C+Raffaele%22">De Caterina, Raffaele</searchLink><br /><searchLink fieldCode="AR" term="%22Hobl%2C+Eva‐Luise%22">Hobl, Eva‐Luise</searchLink><br /><searchLink fieldCode="AR" term="%22Jilma%2C+Bernd%22">Jilma, Bernd</searchLink><br /><searchLink fieldCode="AR" term="%22Christ%2C+Günter%22">Christ, Günter</searchLink><br /><searchLink fieldCode="AR" term="%22Lang%2C+Irene+M%2E%22">Lang, Irene M.</searchLink> ) Array ( [Name] => Publisher [Label] => Publisher Information [Group] => PubInfo [Data] => John Wiley and Sons Inc., 2016. ) Array ( [Name] => DatePubCY [Label] => Publication Year [Group] => Date [Data] => 2016 ) Array ( [Name] => Subject [Label] => Subject Terms [Group] => Su [Data] => <searchLink fieldCode="DE" term="%22Male%22">Male</searchLink><br /><searchLink fieldCode="DE" term="%22Morphine%22">Morphine</searchLink><br /><searchLink fieldCode="DE" term="%22Platelet+Aggregation%22">Platelet Aggregation</searchLink><br /><searchLink fieldCode="DE" term="%22Platelet+Function+Tests%22">Platelet Function Tests</searchLink><br /><searchLink fieldCode="DE" term="%22Abciximab%22">Abciximab</searchLink><br /><searchLink fieldCode="DE" term="%22Antibodies%2C+Monoclonal%22">Antibodies, Monoclonal</searchLink><br /><searchLink fieldCode="DE" term="%22Middle+Aged%22">Middle Aged</searchLink><br /><searchLink fieldCode="DE" term="%22Immunoglobulin+Fab+Fragments%22">Immunoglobulin Fab Fragments</searchLink><br /><searchLink fieldCode="DE" term="%22Humans%22">Humans</searchLink><br /><searchLink fieldCode="DE" term="%22ST+Elevation+Myocardial+Infarction%22">ST Elevation Myocardial Infarction</searchLink><br /><searchLink fieldCode="DE" term="%22Drug+Interactions%22">Drug Interactions</searchLink><br /><searchLink fieldCode="DE" term="%22Female%22">Female</searchLink><br /><searchLink fieldCode="DE" term="%22Prospective+Studies%22">Prospective Studies</searchLink><br /><searchLink fieldCode="DE" term="%22Prasugrel+Hydrochloride%22">Prasugrel Hydrochloride</searchLink> ) Array ( [Name] => Abstract [Label] => Description [Group] => Ab [Data] => The present study investigated whether the glycoprotein (GP)IIb/IIIa receptor blocker abciximab might be a successful bridging strategy to achieve adequate levels of platelet inhibition rapidly in cases where prasugrel is used in morphine-pretreated ST-elevation myocardial infarction (STEMI) patients.In a prospective observational cohort study, 32 patients presenting with STEMI were given prasugrel at a loading dose of 60 mg. Patients were stratified into four groups, according to morphine and/or abciximab use. Adenosine diphosphate (ADP)-induced platelet aggregation was measured at four time points: at baseline, and at 2 h, 1 day and 2 days after prasugrel loading.Morphine use was associated with a three-fold higher level of ADP-induced platelet aggregation 2 h after prasugrel loading compared with no morphine/no abciximab (P = 0.019). However, when abciximab was infused in the catheterization laboratory, the effect of morphine on ADP-induced platelet aggregation disappeared (P = 0.884). This interaction was also seen in the presence of high on-treatment platelet reactivity (HTPR) at 2 h; while HTPR was seen in 88% of morphine users/no abciximab users, it was found in only 17-20% in the three other groups (P = 0.003). The effect of morphine disappeared by day 1 - 2.The infusion of the GPIIb/IIIa receptor blocker abciximab allows immediate and efficient platelet inhibition in STEMI patients concomitantly receiving the oral ADP receptor blocker prasugrel and morphine. ) Array ( [Name] => Language [Label] => Language [Group] => Lang [Data] => English ) Array ( [Name] => URL [Label] => Access URL [Group] => URL [Data] => <link linkTarget="URL" linkTerm="https://explore.openaire.eu/search/publication?articleId=pmid________::0a892e0d75cf4b278917e29b9d016eb1" linkWindow="_blank">https://explore.openaire.eu/search/publication?articleId=pmid________::0a892e0d75cf4b278917e29b9d016eb1</link><br /><link linkTarget="URL" linkTerm="https://europepmc.org/articles/PMC5061801/" linkWindow="_blank">https://europepmc.org/articles/PMC5061801/</link> ) Array ( [Name] => Copyright [Label] => Rights [Group] => Cpyrght [Data] => OPEN ) Array ( [Name] => AN [Label] => Accession Number [Group] => ID [Data] => edsair.pmid..........0a892e0d75cf4b278917e29b9d016eb1 ) |
| RecordInfo |
Array
(
[BibEntity] => Array
(
[Languages] => Array
(
[0] => Array
(
[Text] => English
)
)
[Subjects] => Array
(
[0] => Array
(
[SubjectFull] => Male
[Type] => general
)
[1] => Array
(
[SubjectFull] => Morphine
[Type] => general
)
[2] => Array
(
[SubjectFull] => Platelet Aggregation
[Type] => general
)
[3] => Array
(
[SubjectFull] => Platelet Function Tests
[Type] => general
)
[4] => Array
(
[SubjectFull] => Abciximab
[Type] => general
)
[5] => Array
(
[SubjectFull] => Antibodies, Monoclonal
[Type] => general
)
[6] => Array
(
[SubjectFull] => Middle Aged
[Type] => general
)
[7] => Array
(
[SubjectFull] => Immunoglobulin Fab Fragments
[Type] => general
)
[8] => Array
(
[SubjectFull] => Humans
[Type] => general
)
[9] => Array
(
[SubjectFull] => ST Elevation Myocardial Infarction
[Type] => general
)
[10] => Array
(
[SubjectFull] => Drug Interactions
[Type] => general
)
[11] => Array
(
[SubjectFull] => Female
[Type] => general
)
[12] => Array
(
[SubjectFull] => Prospective Studies
[Type] => general
)
[13] => Array
(
[SubjectFull] => Prasugrel Hydrochloride
[Type] => general
)
)
[Titles] => Array
(
[0] => Array
(
[TitleFull] => Abciximab as a bridging strategy to overcome morphine–prasugrel interaction in STEMI patients
[Type] => main
)
)
)
[BibRelationships] => Array
(
[HasContributorRelationships] => Array
(
[0] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Siller‐Matula, Jolanta M.
)
)
)
[1] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Specht, Simon
)
)
)
[2] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Kubica, Jacek
)
)
)
[3] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Alexopoulos, Dimitrios
)
)
)
[4] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => De Caterina, Raffaele
)
)
)
[5] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Hobl, Eva‐Luise
)
)
)
[6] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Jilma, Bernd
)
)
)
[7] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Christ, Günter
)
)
)
[8] => Array
(
[PersonEntity] => Array
(
[Name] => Array
(
[NameFull] => Lang, Irene M.
)
)
)
)
[IsPartOfRelationships] => Array
(
[0] => Array
(
[BibEntity] => Array
(
[Dates] => Array
(
[0] => Array
(
[D] => 24
[M] => 07
[Type] => published
[Y] => 2016
)
)
[Identifiers] => Array
(
[0] => Array
(
[Type] => issn-locals
[Value] => edsair
)
[1] => Array
(
[Type] => issn-locals
[Value] => edsairFT
)
)
)
)
)
)
)
|
| IllustrationInfo |